Corrigendum: Evidence of tau hyperphosphorylation and dystrophic microglia in the common marmoset [Front. Aging Neurosci., 8, (2016) 315)] DOI: 10.3389/fnagi.2016.00315;Evidence of tau hyperphosphorylation and dystrophic microglia in the common marmoset

Frontiers in Aging Neuroscience

Volumn 8, Issue DEC, 2016, Pages

  Rodriguez Callejas, Juan D ^a   Fuchs, Eberhard ^b   Perez Cruz, Claudia ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b GERMAN PRIMATE CENTER   (Germany)

Author keywords

Aging; Animal models; Neurodegeneration; Non human primate

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; THREONINE;

ADOLESCENT; ADULT; AGED; AGING; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CALLITHRIX JACCHUS; CELL ACTIVATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CORRELATIONAL STUDY; DYSTROPHY; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; NERVE DEGENERATION; NONHUMAN; ONTOGENY; PROTEIN HYPERPHOSPHORYLATION; PROTEIN PHOSPHORYLATION;

EID: 85009516240     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2017.00032     Document Type: Erratum

References (102)

1. Abbott, D., and Barnett, D. (2003). Aspects of common marmoset basic biology and life history important for biomedical research. Comp. Med. 53, 339-350.
2. Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I., and Iqbal, K. (2001). Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. U.S.A. 98, 6923-6928. doi: 10.1073/pnas.121119298
3. Arendt, T., Stieler, J., Strijkstra, A. M., Hut, R. A., Rüdiger, J., Van der Zee, E. A., et al. (2003). Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J. Neurosci. 23, 6972-6981.
4. Asuni, A. A., Boutajangout, A., Quartermain, D., and Sigurdsson, E. M. (2007). Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115-9129. doi: 10.1523/JNEUROSCI.2361-07.2007
5. Avila, J., Santa-María, I., Pérez, M., Hernández, F., and Moreno, F. (2006). Tau phosphorylation, aggregation, and cell toxicity. J. Biomed. Biotechnol. 2006, 1-5. doi: 10.1155/JBB/2006/74539
6. Bellucci, A., Bugiani, O., Ghetti, B., and Spillantini, M. G. (2011). Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener. Dis. 8, 221-229. doi: 10.1159/000322228
7. Bellucci, A., Westwood, A. J., Ingram, E., Casamenti, F., Goedert, M., and Spillantini, M. G. (2004). Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J. Pathol. 165, 1643-1652. doi: 10.1016/S0002-9440(10)63421-9
8. Bi, M., Ittner, A., Ke, Y. D., Götz, J., and Ittner, L. M. (2011). Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS ONE 6:e26860. doi: 10.1371/journal.pone.0026860
9. Bilkei-Gorzo, A. (2014). Genetic mouse models of brain ageing and Alzheimer's disease. Pharmacol. Ther. 142, 244-257. doi: 10.1016/j.pharmthera.2013.12.009
10. Binder, L. I., Guillozet-Bongaarts, A. L., Garcia-Sierra, F., and Berry, R. W. (2005). Tau, tangles, and Alzheimer's disease. Biochim. Biophys. Acta 1739, 216-223. doi: 10.1016/j.bbadis.2004.08.014
11. Blennow, K., de Leon, M. J., and Zetterberg, H. (2006). Alzheimer's disease. Lancet 368, 387-403. doi: 10.1016/S0140-6736(06)69113-7
12. Bolós, M., Llorens-Martín, M., Jurado-Arjona, J., Hernández, F., Rábano, A., and Avila, J. (2016). Direct evidence of internalization of tau by microglia in vitro and in vivo. J. Alzheimer's Dis. 50, 77-87. doi: 10.3233/JAD-150704
13. Bons, N., Rieger, F., Prudhomme, D., Fisher, A., and Krause, K. H. (2006). Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease? Genes Brain Behav. 5, 120-130. doi: 10.1111/j.1601-183X.2005.00149.x
14. Borroni, B., Ferrari, F., Galimberti, D., Nacmias, B., Barone, C., Bagnoli, S., et al. (2014). Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol. Aging 35, .e7-.e10. doi: 10.1016/j.neurobiolaging.2013.09.017
15. Boulouis, G., Charidimou, A., and Greenberg, S. M. (2016). Sporadic cerebral amyloid angiopathy: pathophysiology, neuroimaging features, and clinical implications. Semin. Neurol. 36, 233-243. doi: 10.1055/s-0036-1581993
16. Boutajangout, A., Ingadottir, J., Davies, P., and Sigurdsson, E. M. (2011). Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 118, 658-667. doi: 10.1111/j.1471-4159.2011.07337.x
17. Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259. doi: 10.1007/BF00308809
18. Braak, H., Thal, D. R., Ghebremedhin, E., and Del Tredici, K. (2011). Stages of the pathologic process in Alzheimer disease: age categories From 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960-969. doi: 10.1097/NEN.0b013e318232a379
19. Carlsson, H. E., Schapiro, S. J., Farah, I., and Hau, J. (2004). Use of primates in research: a global overview. Am. J. Primatol. 63, 225-237. doi: 10.1002/ajp.20054
20. Carmel, G., Mager, E. M., Binder, L. I., and Kuret, J. (1996). The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J. Biol. Chem. 271, 32789-32795. doi: 10.1074/jbc.271.51.32789
21. Cha, M. Y., Han, S. H., Son, S. M., Hong, H. S., Choi, Y. J., Byun, J., et al. (2012). Mitochondria-specific accumulation of amyloid β induces mitochondrial dysfunction leading to apoptotic cell death. PLoS ONE 7:e34929. doi: 10.1371/journal.pone.0034929
22. Chai, X., Wu, S., Murray, T. K., Kinley, R., Cella, C. V., Sims, H., et al. (2011). Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J. Biol. Chem. 286, 34457-34467. doi: 10.1074/jbc.M111.229633
23. Chiu, H., Alqadah, A., Chuang, C., and Chang, C. (2011). C. elegans as a genetic model to identify novel cellular and molecular mechanisms underlying nervous system regeneration. Cell Adh. Migr. 5, 387-394. doi: 10.4161/cam.5.5.17985
24. Cork, L., Masters, C., Beyreuther, K., and Price, D. (1990). Development of senile plaques. Relationships of neuronal abnormalities and amyloid deposits. Am. J. Pathol. 137, 1383-1392.
25. Darusman, H. S., Gjedde, A., Sajuthi, D., Schapiro, S. J., Kalliokoski, O., Kristianingrum, Y. P., et al. (2014). Amyloid beta1-42 and the phoshorylated tau threonine 231 in brains of aged Cynomolgus monkeys (Macaca fascicularis). Front. Aging Neurosci. 6:313. doi: 10.3389/fnagi.2014.00313
26. Delobel, P., Flament, S., Hamdane, M., Mailliot, C., Sambo, A. V., Bégard, S., et al. (2002). Abnormal Tau phosphorylation of the Alzheimer-type also occurs during mitosis. J. Neurochem. 83, 412-420. doi: 10.1046/j.1471-4159.2002.01143.x
27. Dickson, T. C., and Vickers, J. C. (2001). The morphological phenotype of β-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience 105, 99-107. doi: 10.1016/S0306-4522(01)00169-5
28. Ferrer, I., López-González, I., Carmona, M., Arregui, L., Dalfó, E., Torrejón-Escribano, B., et al. (2014). Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. J. Neuropathol. Exp. Neurol. 73, 81-97. doi: 10.1097/NEN.0000000000000030
29. Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., and Diamond, M. I. (2015). Distinct therapeutic mechanisms of tau antibodies: promoting microglial clearance versus blocking neuronal uptake. J. Biol. Chem. 290, 21652-21662. doi: 10.1074/jbc.M115.657924
30. García-Sierra, F., Ghoshal, N., Quinn, B., Berry, R. W., and Binder, L. I. (2003). Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J. Alzheimer's Dis. 5, 65-77.
31. Gearing, M., Tigges, J., Mori, H., and Mirra, S. S. (1996). Aβ40 is a major form of beta-amyloid in nonhuman primates. Neurobiol. Aging 17, 903-908. doi: 10.1016/S0197-4580(96)00164-9
32. Gearing, M., Tigges, J., Mori, H., and Mirra, S. S. (1997). β-Amyloid (Aβ) deposition in the brains of aged orangutans. Neurobiol. Aging 18, 139-146. doi: 10.1016/S0197-4580(97)00012-2
33. Gebicke-Haerter, P. J. (2001). Microglia in neurodegeneration: molecular aspects. Microsc. Res. Tech. 54, 47-58. doi: 10.1002/jemt.1120
34. Geula, C., Nagykery, N., and Wu, C.-K. (2002). Amyloid-β; deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition. Acta Neuropathol. 103, 48-58. doi: 10.1007/s004010100429
35. Giannakopoulos, P., Hof, P. R., Michel, J. P., Guimon, J., and Bouras, C. (1997). Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Res. Rev 25, 217-245. doi: 10.1016/S0165-0173(97)00023-4
36. Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., et al. (2013). Alzheimer's disease risk gene cd33 inhibits microglial uptake of amyloid beta. Neuron 78, 631-643. doi: 10.1016/j.neuron.2013.04.014
37. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., et al. (2013). TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127. doi: 10.1056/NEJMoa1211851
38. Härtig, W., Klein, C., Brauer, K., Schüppel, K. F., Arendt, T., Brückner, G., et al. (2000). Abnormally phosphorylated protein tau in the cortex of aged individuals of various mammalian orders. Acta Neuropathol. 100, 305-312. doi: 10.1007/s004010000183
39. Hedden, T., and Gabrieli, J. D. E. (2004). Insights into the ageing mind: a view from cognitive neuroscience. Nat. Rev. Neurosci. 5, 87-96. doi: 10.1038/nrn1323
40. Hof, P. R., Glannakopoulos, P., and Bouras, C. (1996). The neuropathological changes associated with normal brain aging. Histol. Histopathol. 11, 1075-1088.
41. Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., et al. (2013). Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. U.S.A. 110, E3138-E3147. doi: 10.1073/pnas.1301440110
42. Holmes, B. B., Furman, J. L., Mahan, T. E., Yamasaki, T. R., Mirbaha, H., Eades, W. C., et al. (2014). Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl. Acad. Sci. U.S.A. 111, E4376-E4385. doi: 10.1073/pnas.1411649111
43. Huang, L., Merson, T. D., and Bourne, J. A. (2016). In vivo whole brain, cellular and molecular imaging in nonhuman primate models of neuropathology. Neurosci. Biobehav. Rev. 66, 104-118. doi: 10.1016/j.neubiorev.2016.04.009
44. Iqbal, K., and Grundke-Iqbal, I. (2010). Alzheimer disease, a multifactorial disorder seeking multi-therapies. Alzheimers Dement. 6, 420-424. doi: 10.1016/j.jalz.2010.04.006.Alzheimer
45. Iqbal, K., Liu, F., and Gong, C.-X. (2014). Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles. Biochem. Pharmacol. 88, 631-639. doi: 10.1016/j.bcp.2014.01.002.Alzheimer
46. Ishizawa, K., and Dickson, D. W. (2001). Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J. Neuropathol. Exp. Neurol. 60, 647-657. doi: 10.1093/jnen/60.6.647
47. Jicha, G. A., Bowser, R., Kazam, I. G., and Davies, P. (1997a). Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 48, 128-132. doi: 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E
48. Jicha, G. A., Lane, E., Vincent, I., Otvos, L., Hoffmann, R., and Davies, P. (1997b). A conformation-and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J. Neurochem. 69, 2087-2095. doi: 10.1046/j.1471-4159.1997.69052087.x
49. Kimura, N., Tanemura, K., Nakamura, S. I., Takashima, A., Ono, F., Sakakibara, I., et al. (2003). Age-related changes of Alzheimer's disease-associated proteins in cynomolgus monkey brains. Biochem. Biophys. Res. Commun. 310, 303-311. doi: 10.1016/j.bbrc.2003.09.012
50. Kitazawa, M. (2005). Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 8843-8853. doi: 10.1523/JNEUROSCI.2868-05.2005
51. Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., et al. (2014). TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 6, 1-12. doi: 10.1126/scitranslmed.3009093
52. Lacor, P., Buniel, M., Chang, L., Fernández, S., Gong, Y., Viola, K., et al. (2004). Synaptic targeting by Alzheimer's-related amyloid β oligomers. J. Neurosci. 24, 10191-10200. doi: 10.1523/JNEUROSCI.3432-04.2004
53. Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wiseniewski, T., Saido, T. C., and Selkoe, D. J. (1996). Sequence of deposition of heterogenous amyloid β-peptides and the APO E in Down syndrome: implication for the intial events in amyloid plaque formation. Neurobiol. Dis. 3, 16-32. doi: 10.1006/nbdi.1996.0003
54. Lemere, C. A., Oh, J., Stanish, H. A., Peng, Y., Pepivani, I., Fagan, A. M., et al. (2008). Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease? Rejuvenation Res. 11, 321-332. doi: 10.1089/rej.2008.0677
55. Leuner, B., Kozorovitskiy, Y., Gross, C. G., and Gould, E. (2007). Diminished adult neurogenesis in the marmoset brain precedes old age. Proc. Natl. Acad. Sci. U.S.A. 104, 17169-17173. doi: 10.1073/pnas.0708228104
56. Lindwall, G., and Cole, R. D. (1984). Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301-5305.
57. Lombardo, J. A., Stern, E. A., McLellan, M. E., Kajdasz, S. T., Hickey, G. A., Bacskai, B. J., et al. (2003). Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23, 10879-10883.
58. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The hallmarks of aging. Cell 153, 1194-1217. doi: 10.1016/j.cell.2013.05.039
59. Luo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., and Paul, S. M. (2015). Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci. Rep. 5, 1-12. doi: 10.1038/srep11161
60. Mackenzie, I. R. A. (1994). Senile plaques do not progressively accumulate with normal aging. Acta Neuropathol. 87, 520-525. doi: 10.1007/s004010050118
61. Maclean, C. J., Baker, H. F., Ridley, R. M., and Mori, H. (2000). Naturally occurring and experimentally induced beta-amyloid deposits in the brains of marmosets (Callithrix jacchus). J. Neural Transm. 107, 799-814. doi: 10.1007/s007020070060
62. Maphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff, R. M., et al. (2015). Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain J. Neurol. 138, 1738-1755. doi: 10.1093/brain/awv081
63. Masliah, E., Terry, R. D., Mallory, M., Alford, M., and Hansen, L. A. (1990). Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am. J. Pathol. 137, 1293-1297.
64. Mitchell, S. J., Scheibye-Knudsen, M., Longo, D. L., and De Cabo, R. (2015). Animal models of aging research: implications for human aging and age-related diseases. Annu. Rev. Anim. Biosci 3, 283-303. doi: 10.1146/annurev-animal-022114-110829
65. Mufson, E. J., Chen, E., Cochran, E. J., Beckett, L. A., Bennett, D. A., and Kordower, J. H. (1999). Entorhinal cortex β-amyloid load in individuals with mild cognitive impairment. Exp. Neurol. 158, 469-490. doi: 10.1006/exnr.1999.7086
66. Oikawa, N., Kimura, N., and Yanagisawa, K. (2010). Alzheimer-type tau pathology in advanced aged nonhuman primate brains harboring substantial amyloid deposition. Brain Res. 1315, 137-149. doi: 10.1016/j.brainres.2009.12.005
67. Okano, H., Hikishima, K., Iriki, A., and Sasaki, E. (2012). The common marmoset as a novel animal model system for biomedical and neuroscience research applications. Semin. Fetal Neonatal Med. 17, 336-340. doi: 10.1016/j.siny.2012.07.002
68. Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., et al. (2007). Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697-711. doi: 10.1016/j.neuron.2007.07.025
69. Paxinos, G., Watson, C., Petrides, M., Rosa, M., and Tokuno, H. (2012). The Marmoset Brain in Stereotaxic Coordinates, 1st Edn. San Diego, CA: Elsevier Inc.
70. Perez, S. E., Raghanti, M. A., Hof, P. R., Kramer, L., Ikonomovic, M. D., Lacor, P. N., et al. (2013). Alzheimer's disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla). J. Comp. Neurol. 521, 4318-4338. doi: 10.1002/cne.23428
71. Rodrigue, K. M., Kennedy, K. M., and Park, D. C. (2009). Beta-amyloid deposition and the aging brain. Neuropsychol. Rev. 19, 436-450. doi: 10.1007/s11065-009-9118-x.Beta-Amyloid
72. Ross, C. N., Davis, K., Dobek, G., and Tardif, S. D. (2012). Aging phenotypes of common marmosets (Callithrix jacchus). J. Aging Res. 2012, 1-6. doi: 10.1155/2012/567143
73. Sasahara, K., Morigaki, K., and Shinya, K. (2013). Effects of membrane interaction and aggregation of amyloid β-peptide on lipid mobility and membrane domain structure. Phys. Chem. Chem. Phys. 15, 8929-8939. doi: 10.1039/c3cp44517h
74. Schultz, C., Dehghani, F., Hubbard, G. B., Thal, D. R., Struckhoff, G., Braak, E., et al. (2000a). Filamentous tau pathology in nerve cells, astrocytes, and oligodendrocytes of aged baboons. J. Neuropathol. Exp. Neurol. 59, 39-52. doi: 10.1093/jnen/59.1.39
75. Schultz, C., Hubbard, G. B., Rüb, U., Braak, E., and Braak, H. (2000b). Age-related progression of tau pathology in brains of baboons. Neurobiol. Aging 21, 905-912. doi: 10.1016/S0197-4580(00)00176-7
76. Scientific Committee on Health and Environmental Risks. (2009). The Need for non-Human Primates in Biomedical Research, Production and Testing of Products and Devices. Brussels: European Commission.
77. Selkoe, D. J., Bell, D. S., Podlisny, M. B., Price, D. L., and Cork, L. C. (1987). Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 235, 873-877. doi: 10.1126/science.3544219
78. Sengupta, U., Nilson, A. N., and Kayed, R. (2016). The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 6, 42-49. doi: 10.1016/j.ebiom.2016.03.035
79. Simmons, D. A., Casale, M., Alcon, B., Pham, N. H. A., Narayan, N., and Lynch, G. (2007). Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 55, 1074-1084. doi: 10.1002/glia
80. Sridharan, A., Pehar, M., Salamat, M. S., Pugh, T. D., Bendlin, B. B., Willette, A. A., et al. (2013). Calorie restriction attenuates astrogliosis but not amyloid plaque load in aged rhesus macaques: a preliminary quantitative imaging study. Brain Res. 1508, 1-8. doi: 10.1016/j.brainres.2013.02.046
81. Stokin, G. B., and Goldstein, L. S. B. (2006). Axonal transport and Alzheimer's disease. Annu. Rev. Biochem. 75, 607-627. doi: 10.1146/annurev.biochem.75.103004.142637
82. Streit, W. J., Braak, H., Xue, Q. S., and Bechmann, I. (2009). Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 118, 475-485. doi: 10.1007/s00401-009-0556-6
83. Streit, W. J., Sammons, N. W., Kuhns, A. J., and Sparks, D. L. (2004). Dystrophic microglia in the aging human brain. Glia 45, 208-212. doi: 10.1002/glia.10319
84. Tardif, S. D., Mansfield, K. G., Ratnam, R., Ross, C. N., and Ziegler, T. E. (2011). The marmoset as a model of aging and age-related diseases. ILAR J. 52, 54-65. doi: 10.1016/j.biotechadv.2011.08.021
85. Teo, L., Rosenfeld, J. V., and Bourne, J. A. (2012). Models of CNS injury in the nonhuman primate: a new era for treatment strategies. Transl. Neurosci. 3, 181-195. doi: 10.2478/s13380-012-0023-z
86. T'Hart, B. A., Abbott, D. H., Nakamura, K., and Fuchs, E. (2012). The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease. Drug Discov. Today 17, 1160-1165. doi: 10.1016/j.drudis.2012.06.009
87. Tomobe, K., and Nomura, Y. (2009). Neurochemistry, neuropathology, and heredity in samp8: a mouse model of senescence. Neurochem. Res. 34, 660-669. doi: 10.1007/s11064-009-9923-x
88. von Eitzen, U., Egensperger, R., Kösel, S., Grasbon-Fordl, E. M., Imai, Y., Bise, K., et al. (1998). Microglia and the development of spongiform change in Creutzfeld-Jakob disease. J. Neuropathol. Exp. Neurol. 57, 246-256. doi: 10.1017/CBO9781107415324.004
89. Weaver, C. L., Espinoza, M., Kress, Y., and Davies, P. (2000). Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol. Aging 21, 719-727. doi: 10.1016/S0197-4580(00)00157-3
90. Wierzba-Bobrowicz, T., Lewandowska, E., Kosno-Kruszewska, E., Lechowicz, W., Pasennik, E., and Schmidt-Sidor, B. (2004). Degeneration of microglial cells in frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol. 42, 157-165.
91. Woodruff-Pak, D. S. (2008). Animal models of Alzheimer's disease: therapeutic implications. J. Alzheimer's Dis. 15, 507-521.
92. World Health Organization. (2015). World Report on Ageing and Health. Geneva: World Health Organization.
93. Wu, C.-K., Nagykery, N., Hersh, L., Scinto, L. F., and Geula, C. (2003). Selective age-related loss of calbindin-D28k from basal forebrain cholinergic neurons in the common marmoset (Callithrix jacchus). Neuroscience 120, 249-259. doi: 10.1016/S0306-4522(03)00248-3
94. Xue, Q. S., and Streit, W. J. (2011). Microglial pathology in down syndrome. Acta Neuropathol. 122, 455-466. doi: 10.1007/s00401-011-0864-5
95. Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., et al. (2013). Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-414. doi: 10.1016/j.neuron.2013.07.046
96. Yeoman, M., Scutt, G., and Faragher, R. (2012). Insights into CNS ageing from animal models of senescence. Nat. Rev. Neurosci. 13, 435-445. doi: 10.1038/nrn3230
97. Yeoman, M. S., and Faragher, R. G. A. (2001). Ageing and the nervous system: insights from studies on invertebrates. Biogerontology 2, 85-97. doi: 10.1023/A:1011597420036
98. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T., et al. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351. doi: 10.1016/j.neuron.2007.01.010
99. Yu, W., and Lu, B. (2012). Synapses and dendritic spines as pathogenic targets in Alzheimer's disease. Neural Plast. 2012, 1-8. doi: 10.1155/2012/247150
100. Zhang, H., Ma, Q., Zhang, Y., and Xu, H. (2012). Proteolytic processing of Alzheimer's β-amyloid precursor protein. J. Neurochem. 120, 9-21. doi: 10.1111/j.1471-4159.2011.07519.x
101. Zheng-Fischhöfer, Q., Biernat, J., Mandelkow, E. M., Illenberger, S., Godemann, R., and Mandelkow, E. (1998). Sequential phosphorylation of Tau by glycogen synthase kinase-3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur. J. Biochem. 252, 542-552. doi: 10.1046/j.1432-1327.1998.2520542.x
102. Zilka, N., Stozicka, Z., Kovac, A., Pilipcinec, E., Bugos, O., and Novak, M. (2009). Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J. Neuroimmunol. 209, 16-25. doi: 10.1016/j.jneuroim.2009.01.013